oncology

Zucarfil (Carfilzomib Injection 60 mg) – Product Description Zucarfil contains Carfilzomib 60 mg, a targeted anti-cancer medicine used for the treatment of relapsed or refractory multiple myeloma (RRMM). It belongs to the proteasome inhibitor class of medicines and works by irreversibly blocking the 20S proteasome, causing the accumulation of damaged proteins within cancer cells. This leads to cellular stress and programmed cancer cell death (apoptosis), helping slow disease progression. Zucarfil is supplied as a lyophilized powder for intravenous (IV) infusion and is administered by qualified healthcare professionals. It is commonly used in combination with medicines such as dexamethasone, lenalidomide, or daratumumab, depending on the patient's treatment regimen and clinical condition. Active Ingredient Carfilzomib 60 mg Dosage Form Lyophilized Powder for Injection (IV Infusion) Therapeutic Indications Relapsed Multiple Myeloma Refractory Multiple Myeloma Multiple Myeloma Combination Therapy Other approved indications as determined by the treating oncologist How It Works Carfilzomib selectively and irreversibly inhibits the 20S proteasome, preventing the breakdown of unwanted proteins inside cancer cells. The resulting protein buildup disrupts normal cell function, triggering apoptosis and reducing the growth of multiple myeloma cells. Key Features Targeted proteasome inhibitor for multiple myeloma Effective in relapsed and refractory disease Administered by intravenous infusion under specialist supervision Commonly used in combination with established myeloma therapies Manufactured according to stringent pharmaceutical quality standards Storage Store refrigerated at 2°C–8°C. Protect from light and do not freeze. Keep out of reach of children. Note: Zucarfil (Carfilzomib Injection 60 mg) is a prescription-only medicine and should be administered only by qualified healthcare professionals experienced in oncology. Patients should be monitored regularly for blood counts, kidney function, liver function, cardiac status, and infusion-related reactions throughout treatment.

Zucarb (Carboplatin Injection) – Product Description Zucarb contains Carboplatin, a prescription platinum-based chemotherapy medicine used in the treatment of various solid tumors, including ovarian cancer, lung cancer, head and neck cancer, and other malignancies. It belongs to the platinum-containing antineoplastic agents and works by damaging the DNA of cancer cells, preventing their growth and division, ultimately leading to cancer cell death. Zucarb is administered as an intravenous (IV) infusion by qualified healthcare professionals. It may be used alone or in combination with other chemotherapy medicines depending on the type and stage of cancer, as well as the patient's overall treatment plan. Active Ingredient Carboplatin Dosage Form Sterile Injection for Intravenous (IV) Infusion Therapeutic Indications Ovarian Cancer Non-Small Cell Lung Cancer (NSCLC) Small Cell Lung Cancer (SCLC) Head and Neck Cancer Endometrial Cancer Other solid tumors as recommended by the treating oncologist How It Works Carboplatin forms DNA cross-links within cancer cells, preventing DNA replication and repair. This disrupts cell division and triggers the death of rapidly dividing cancer cells, helping to slow or stop tumor growth. Key Features Platinum-based chemotherapy with proven clinical efficacy Effective against a wide range of solid tumors Suitable for use as monotherapy or combination chemotherapy Administered under specialist oncology supervision Manufactured according to stringent pharmaceutical quality standards Storage Store according to the manufacturer's recommendations. Protect from excessive heat, freezing, and direct light. Keep out of reach of children. Note: Zucarb (Carboplatin Injection) is a prescription-only chemotherapy medicine and should only be administered by qualified healthcare professionals experienced in oncology. Regular monitoring of blood counts, kidney function, liver function, andelectrolyte levels is recommended throughout treatment.

Zovorin Injection (Leucovorin Calcium Injection 50 mg) – Product Description Zovorin Injection contains Leucovorin Calcium 50 mg, a folinic acid (reduced folic acid) medicine widely used in oncology and supportive cancer care. It is primarily administered to reduce the toxic effects of high-dose methotrexate therapy (leucovorin rescue) and to enhance the effectiveness of 5-Fluorouracil (5-FU) in the treatment of colorectal cancer. Leucovorin is also indicated for the treatment of certain folate deficiency conditions when oral therapy is not suitable. It is administered by qualified healthcare professionals through intravenous (IV) or intramuscular (IM) injection according to the prescribed treatment protocol. Active Ingredient Leucovorin Calcium 50 mg Dosage Form Sterile Injection Therapeutic Indications High-Dose Methotrexate Rescue Therapy Colorectal Cancer (in combination with 5-Fluorouracil) Folate Deficiency requiring injectable treatment Other approved indications as determined by the treating physician How It Works Leucovorin is an active form of folic acid that helps protect normal cells from the toxic effects of methotrexate without reducing its anti-cancer activity. When used with 5-Fluorouracil (5-FU), it enhances the binding of 5-FU to its target enzyme, improving the chemotherapy's effectiveness against cancer cells. Key Features Provides effective rescue following high-dose methotrexate therapy Enhances the efficacy of 5-Fluorouracil in colorectal cancer treatment Supports healthy folate metabolism Suitable for intravenous or intramuscular administration Manufactured according to stringent pharmaceutical quality standards Storage Store according to the manufacturer's recommendations. Protect from light and excessive heat. Keep out of reach of children. Note: Zovorin Injection (Leucovorin Calcium 50 mg) is a prescription-only medicine and should be administered only under the supervision of qualified healthcare professionals. Treatment should follow established oncology protocols with appropriate clinical monitoring.